In the article by Kato et al., which published in the May 2019 issue of PAIN®, the authors note that they made an error in Figure 3, noting the mirogabalin dose as ‘QD’, rather than the correct ‘per day’. The corrected figure and caption is shown below:
The authors apologize for the error.
Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. PAIN 2019;160:1175-85.